Attached files
| file | filename |
|---|---|
| EX-23.3 - EX-23.3 - Atea Pharmaceuticals, Inc. | d913778dex233.htm |
| EX-10.10 - EX-10.10 - Atea Pharmaceuticals, Inc. | d913778dex1010.htm |
| EX-10.9 - EX-10.9 - Atea Pharmaceuticals, Inc. | d913778dex109.htm |
| EX-10.5 - EX-10.5 - Atea Pharmaceuticals, Inc. | d913778dex105.htm |
| EX-10.4 - EX-10.4 - Atea Pharmaceuticals, Inc. | d913778dex104.htm |
| EX-10.3 - EX-10.3 - Atea Pharmaceuticals, Inc. | d913778dex103.htm |
| EX-10.2 - EX-10.2 - Atea Pharmaceuticals, Inc. | d913778dex102.htm |
| EX-5.1 - EX-5.1 - Atea Pharmaceuticals, Inc. | d913778dex51.htm |
| EX-3.4 - EX-3.4 - Atea Pharmaceuticals, Inc. | d913778dex34.htm |
| EX-3.3 - EX-3.3 - Atea Pharmaceuticals, Inc. | d913778dex33.htm |
| EX-3.1.1 - EX-3.1.1 - Atea Pharmaceuticals, Inc. | d913778dex311.htm |
| EX-1.1 - EX-1.1 - Atea Pharmaceuticals, Inc. | d913778dex11.htm |
| S-1/A - AMENDMENT 2 TO FORM S-1 - Atea Pharmaceuticals, Inc. | d913778ds1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Atea Pharmaceuticals, Inc.:
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
Boston, Massachusetts
October 25, 2020